


# Corporate Profile / Main Group Companies

## Corporate Profile

(As of April 1, 2020)

Company name DAIICHI SANKYO CO., LTD.  
 Established September 28, 2005  
 Business Research and development, manufacturing, import, sales, and marketing of pharmaceutical products  
 Share capital ¥50,000 million  
 Headquarters 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan  
 Branches Sapporo, Tohoku, Tokyo, Chiba, Saitama, Yokohama, Kanetsu, Tokai, Kyoto, Osaka, Kobe, Chugoku, Shikoku, and Kyushu



**9.7% Europe**

- Daiichi Sankyo Europe GmbH
- Daiichi Sankyo Deutschland GmbH
- Daiichi Sankyo France SAS
- Daiichi Sankyo Italia S.p.A.
- Daiichi Sankyo España, S.A.U.
- Daiichi Sankyo UK Ltd.
- Daiichi Sankyo (Schweiz) AG
- Daiichi Sankyo Portugal, Unipessoal Lda.
- Daiichi Sankyo Austria GmbH
- Daiichi Sankyo Belgium N.V.-S.A.
- Daiichi Sankyo Nederland B.V.
- Daiichi Sankyo Ilac Ticaret Ltd. Şti.
- Daiichi Sankyo Ireland Ltd.
- Daiichi Sankyo Altkirch Sarl

Revenue (Billions of yen)			
	FY2018 Results	FY2019 Results	YoY
<b>Daiichi Sankyo Europe</b>	<b>88.6</b>	<b>95.5</b>	<b>+6.9</b>
LIXIANA	45.8	61.7	+15.9
Olmesartan	27.4	24.6	-2.8
Effient	5.7	2.5	-3.2

**61.3% Japan**

- Daiichi Sankyo Espha Co., Ltd.
- Daiichi Sankyo Healthcare Co., Ltd.
- Daiichi Sankyo Propharma Co., Ltd.
- Daiichi Sankyo Chemical Pharma Co., Ltd.
- Daiichi Sankyo Biotech Co., Ltd.
- Daiichi Sankyo RD Novare Co., Ltd.
- Daiichi Sankyo Business Associe Co., Ltd.
- Daiichi Sankyo Happiness Co., Ltd.

Revenue (Billions of yen)			
	FY2018 Results	FY2019 Results	YoY
<b>Domestic Prescription Drug and Vaccine Business</b>	<b>523.3</b>	<b>533.5</b>	<b>+10.2</b>
LIXIANA	64.9	83.0	+18.1
NEXIUM	78.3	79.8	+1.5
Memary	50.2	50.5	+0.3
PRALIA	27.4	30.9	+3.6
TENELIA	25.3	24.7	-0.6
Loxonin	30.5	28.3	-2.2
Inavir	18.2	19.3	+1.1
RANMARK	16.4	17.9	+1.5
Effient	13.9	14.0	+0.1
Rezaltas	15.5	14.6	-0.9
CANALIA	9.2	12.8	+3.6
VIMPAT	6.6	11.2	+4.6
Omnipaque	12.0	10.3	-1.7
Olmotec	14.9	11.7	-3.2
Tarige	-	8.0	+8.0
<b>Daiichi Sankyo Healthcare (OTC Related)</b>	<b>66.4</b>	<b>68.5</b>	<b>+2.1</b>

Sales Manufacturing Research and development

**10.0% ASCA\***

- Daiichi Sankyo (China) Holdings Co., Ltd.
- Daiichi Sankyo Taiwan Ltd.
- Daiichi Sankyo Korea Co., Ltd.
- Daiichi Sankyo (Thailand) Ltd.
- Daiichi Sankyo Hong Kong Ltd.
- Daiichi Sankyo Brasil Farmaceutica LTDA.

Revenue (Billions of yen)			
	FY2018 Results	FY2019 Results	YoY
<b>Asia, South &amp; Central America (ASCA)</b>	<b>87.7</b>	<b>98.3</b>	<b>+10.7</b>
Daiichi Sankyo China	38.5	46.0	+7.6
Daiichi Sankyo Korea	15.7	17.2	+1.5
Daiichi Sankyo Brasil	10.0	11.5	+1.5
Daiichi Sankyo Taiwan	7.1	7.6	+0.5
Daiichi Sankyo Thailand	3.3	3.3	+0.1

## Number of Bases

(As of March 31, 2020)

Group companies	Number of countries with bases	R&D bases	Production bases
<b>49</b>	<b>24</b>	<b>14</b> bases in <b>8</b> countries	<b>14</b> bases in <b>6</b> countries

**16.6% U.S.A.**

- Daiichi Sankyo, Inc.
- American Regent, Inc.
- Plexxikon Inc.

Revenue (Billions of yen)			
	FY2018 Results	FY2019 Results	YoY
<b>Daiichi Sankyo, Inc.</b>	<b>36.3</b>	<b>32.1</b>	<b>-4.2</b>
Olmesartan	10.7	9.8	-0.9
Welchol	13.4	9.1	-4.3
Enheru	-	3.2	+3.2
SAVAYSA	2.3	2.6	+0.3
Effient	2.4	0.5	-2.0
<b>American Regent, Inc.</b>	<b>117.8</b>	<b>130.8</b>	<b>+13.0</b>
Injectafer	44.2	51.8	+7.6
Venofer	28.9	31.0	+2.1